Tissue & cell · 2025
Exploring the direct influence of growth hormone on adamantinomatous craniopharyngioma cells.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Xiong Zhiwei, Li Kai, Yu Milai, Wang Zijing, Wang Yihan, Chen Rongjun, Li Weizhao, Zhang Keying, Lin Yucong, Zhang Zhixuan, Meng Haochuan, Pu Guowu, Li Danling, Cao Yongfu, Peng Junxiang
Аннотация
PURPOSE: This study aims to investigate the impact of growth hormone therapy on the postoperative management of craniopharyngioma and to evaluate the direct influence of growth hormone (GH) on craniopharyngioma.
METHODS: The research involved the application of varying concentrations of growth hormone to stimulate and cultivate the adamantinomatous craniopharyngioma (ACP) cell line. It focused on assessing the influence of growth hormone on the growth, proliferation, and apoptosis of ACP cells, and explored changes in transcription levels following growth hormone treatment of ACP cells through transcriptome sequencing. The results shed light on the effects and underlying mechanisms through which growth hormone impacts ACP cells.
RESULTS: ACP cells were treated with different concentrations of growth hormone (0.01, 0.05, 0.1, 0.5, 1, 10 μg/ml) for 24, 48, and 72 hours. The CCK8 cell viability assay's results indicate that growth hormone stimulation does not significantly increase ACP cell proliferation. Furthermore, sequencing data analysis suggests that growth hormone does not promote the activation of pathways associated with craniopharyngioma proliferation. Immunofluorescence analysis confirmed the presence of GHR receptors on ACP cells. Moreover, flow cytometry experiments focusing on cell cycle and apoptosis in ACP cells show that growth hormone does not affect cell cycle progression or apoptosis.
CONCLUSION: The findings suggest that growth hormone can impact craniopharyngioma directly but it didn't promote the growth of ACP.
METHODS: The research involved the application of varying concentrations of growth hormone to stimulate and cultivate the adamantinomatous craniopharyngioma (ACP) cell line. It focused on assessing the influence of growth hormone on the growth, proliferation, and apoptosis of ACP cells, and explored changes in transcription levels following growth hormone treatment of ACP cells through transcriptome sequencing. The results shed light on the effects and underlying mechanisms through which growth hormone impacts ACP cells.
RESULTS: ACP cells were treated with different concentrations of growth hormone (0.01, 0.05, 0.1, 0.5, 1, 10 μg/ml) for 24, 48, and 72 hours. The CCK8 cell viability assay's results indicate that growth hormone stimulation does not significantly increase ACP cell proliferation. Furthermore, sequencing data analysis suggests that growth hormone does not promote the activation of pathways associated with craniopharyngioma proliferation. Immunofluorescence analysis confirmed the presence of GHR receptors on ACP cells. Moreover, flow cytometry experiments focusing on cell cycle and apoptosis in ACP cells show that growth hormone does not affect cell cycle progression or apoptosis.
CONCLUSION: The findings suggest that growth hormone can impact craniopharyngioma directly but it didn't promote the growth of ACP.